Array Licenses TLR Program To VentiRx, Keeps Cancer Option March 14, 2007 By Trista Morrison A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)Read More
RSS